Hematopoietic stem-cell transplantation (HSCT) refers to a procedure in which hematopoietic stem cells are infused to restore bone marrow function in cancer patients who receive bone-marrowtoxic doses of cytotoxic drugs, with or without whole body radiation therapy. Stem cells may be obtained from the transplant recipient (autologous HSCT) or can be harvested from a donor (allogeneic HSCT). Ste...

Background: Umbilical cord blood (UCB) is an alternative source of hematopoietic stem cell transplantation (HSCT), used in Leukemia treatment. CD26+ cells, a fraction of CD34 positive cells, are a major population of UCB cells which negatively regulate the in vivo homing and engraftment of HSCs. CD26 is highly expressed in various cells such as HSCs, immune cells, fibroblasts, and epithelial ce...

More than 25,000 hematopoietic stem cell transplantations (HSCTs) are performed each year for the treatment of lymphoma, leukemia, immune-deficiency illnesses, congenital metabolic defects, hemoglobinopathies, and myelodysplastic and myeloproliferative syndromes. Before transplantation, patients receive intensive myeloablative chemoradiotherapy followed by stem cell "rescue." Autologous HSCT is...

Autoimmune diseases are an important field for the development of hematopoietic stem cell transplantation (HSCT). The Brazilian Society Cellular Therapy and Bone Marrow Transplantation (Sociedade Brasileira de Terapia Celular e Transplante Medula Óssea, SBTMO) organized consensus meetings Diseases Group, to review available literature on HSCT autoimmune diseases, aiming gather data that support...

CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation have cosponsored these guidelines for preventing opportunistic infections (OIs) among hematopoietic stem cell transplant (HSCT) recipients. The guidelines were drafted with the assistance of a working group of experts in infectious diseases, transplantation, and public health. For the pu...

introduction: allogeneic hematopoietic cell transplantation (hsct) is the only therapeutic modality capable of correcting the hematologic manifestations of fanconi anemia (fa). the development  of well  tolerated,  immunosuppressive  conditioning  regimens  for fa patients  undergoing hsct has proven to be a rather challenging task for hematologists. methods: we analyzed the outcome of 30 fa pa...

The first hematopoietic stem cell transplantation (HSCT) program in Latin America started 1979 at the federal university hospital Curitiba, Paraná, Brazil. Over years, number of centers performing transplants our country has increased tremendously, generating need to know results this treatment modality. Understanding HSCT scenario Brazil is still challenging, since not all Brazilian report dat...

: Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for many malignant and nonmalignant diseases. However, chronic graft-versus-host disease (cGVHD) remains a significant cause of late morbidity and mortality after allogeneic HSCT. cGVHD often manifests as autoimmune syndrome. Thymic epithelial cells (TECs) play a critical role in supporting negative se...

the increased risk of hemolytic reactions and erythrocyte recovery delay in abo incompatible hematopoietic stem cell transplantation (hsct) is well established. effects of abo incompatibility on transplantation outcomes is evaluated in this study. we prospectively followed 501 patients undergoing allogeneic stem cell transplantation according to abo compatibility groups of minor, major and bidi...

OBJECTIVE The aim of this study was to document hematopoietic stem cell transplantation (HSCT) activity and trends at our treatment center. MATERIAL AND METHODS Data collected over a 10-year period were retrospectively analyzed, concentrating primarily on types of HSCT, transplant-related mortality (TRM), stem cell sources, indications for HSCT, and causes of death following HSCT. RESULTS I...